![](/img/cover-not-exists.png)
484PRetrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)
Sobrero, A, Lenz, H-J, Eng, C, Scheithauer, W, Middleton, G, Chen, W, Esser, R, Nippgen, J, Burris, HVolume:
29
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy281.032
Date:
October, 2018
File:
PDF, 75 KB
2018